CGBIO Signs Agreement with Curexo for CUVIS-spine

CGBIO signed an exclusive domestic distribution agreement for the spinal surgery robot CUVIS-spine, developed by Curexo.

Under the agreement, CGBIO will take full responsibility for the domestic sales and marketing of the system. CUVIS-spine is a surgical robot that precisely guides the robotic arm during pedicle screw insertion procedures according to pre-established surgical plans. It features a high-precision navigation system that provides a stable surgical environment, enhancing surgical accuracy while reducing radiation exposure for both medical staff and patients.

By incorporating surgical robots into its portfolio, CGBIO will move beyond supplying individual products such as implants and bone substitutes separately, and instead establish an advanced digital spinal surgery solution that enables integrated planning of screw insertion pathways and implant selection based on robotic navigation prior to surgery.

Last year, CGBIO and Curexo signed a memorandum of understanding to jointly develop an integrated spinal surgery platform based on CUVIS-spine. The exclusive domestic distribution agreement represents a follow-up phase that expands the partnership from the research and development stage to actual clinical practice and market application.

CGBIO CEO Hyunseung Yoo stated, “This agreement marks an important turning point in transforming CGBIO’s spinal surgery strategy by integrating digital technology into advanced medical environments.” He added, “Building on the spinal implants, biomaterials, and clinical network capabilities that CGBIO has accumulated, we will present an integrated solution that encompasses surgical robotic platforms. Starting with this agreement, we plan to roll out phased sales and marketing activities for CUVIS-spine, focusing on major university hospitals and specialized spinal hospitals.”

Source: kndaily.co.kr